Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,312Revenue (TTM) $M1.3Net Margin (%)-19,049.6Altman Z-Score-1.0
Enterprise Value $M1,209EPS (TTM) $-5.4Operating Margin %-18,995.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.3Pre-tax Margin (%)-19,049.6Higher ROA y-yN
Price/Book10.310-y EBITDA Growth Rate %2.4Quick Ratio2.3Cash flow > EarningsY
Price/Sales9135-y EBITDA Growth Rate %36.1Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-107.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-161.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M47.9ROIC % (ttm)-786.8Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 27.4863%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 27.4822%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 27.48-13%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 27.488%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 27.48-7%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 27.48-28%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 27.48-5%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 27.483%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.51)
$ 27.48322%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.96)
$ 27.48454%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 27.48250%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 27.48184%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.2868.3view
Barry RichardDirector 2016-03-14Buy75,000$15.6674.97view
Price Ben GilDirector 2016-03-14Buy4,500$16.764.07view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82131.81view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82131.81view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9596.42view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.56118.15view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-26.03view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-21.65view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-16.16view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
What's behind put volume in Sarepta Aug 23 2016
SAREPTA THERAPEUTICS, INC. Financials Aug 18 2016
Sarepta Therapeutics: Patience Will Not Be Rewarded Aug 10 2016
Sarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines' Aug 10 2016
Sarepta Therapeutics: Here We Go Again Aug 10 2016
[$$] Heart of Bureaucratic Darkness Aug 09 2016
[$$] Heart of Bureaucratic Darkness Aug 09 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 09 2016
Sarepta (SRPT) Stock Advances on Phase III Trial Recruitment Aug 03 2016
Why Sarepta Therapeutics is Soaring Aug 03 2016
How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company Jul 28 2016
Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate... Jul 26 2016
Sarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss Jul 20 2016
Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus Jul 20 2016
Morning Movers: Morgan Stanley Jumps on Earnings; Valeant Pharmaceuticals Climbs on Drug Approval Jul 20 2016
Sarepta Therapeutics reports 2Q loss Jul 19 2016
Sarepta Therapeutics reports 2Q loss Jul 19 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)